Sangamo Therapeutics(NASDAQ) SGMO

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-99%
5 Year-98%
1 Year-79%
1 Month-10%
N/A
Sangamo Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.142026-10-05
Sangamo Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.77%USD 0.142026-09-28
1 month-10.43%USD 0.162026-09-04
3 month+110.97%USD 0.072026-07-07
Year to date-65.67%USD 0.422025-12-31
1 year-78.88%USD 0.682025-10-03
3 year-73.78%USD 0.552023-10-06
5 year-98.35%USD 8.722021-10-06
Since inception-99.04%USD 15.062000-04-06

Sangamo Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$34.56

Net Income (TTM)

-$123.33

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

SGMO News

genetics3

CRISPR 101: What Investors Need to Know

Matt Frankel, CFP®Jun 5, 2021
getty-woman-w-surgical-mask

3 Top Biotech Stocks to Watch in July

Alex CarchidiJul 9, 2020
Doctor blood vial

Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial

Brian Orelli, PhDJun 18, 2020
GettyImages-1187059346

Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics

Alex CarchidiJun 14, 2020
Female scientist holding 2 test tubes

Better Buy: Cara Therapeutics vs. Sangamo Therapeutics

Keith SpeightsApr 29, 2020
GettyImages-1145759798

Better Buy: Editas Medicine vs Sangamo Therapeutics

Mark PrvulovicApr 1, 2020
GettyImages-1167797053

3 Top Stocks You've Probably Never Heard Of

Mark PrvulovicMar 28, 2020
GettyImages-1070162470

Better Buy: CRISPR Therapeutics vs. Sangamo Biosciences

David HaenMar 19, 2020
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Industry

Biotechnology

Sector

Health Care

Employees

142

CEO

Alexander D. Macrae, PhD

Website

www.sangamo.com

SGMO Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Sangamo Therapeutics Performance Analysis

Sangamo Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 111,299,0000.5%
20232023-12-31USD 176,232,00058.3%
20242024-12-31USD 57,800,000-67.2%
20252025-12-31USD 39,552,000-31.6%
Sangamo Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.251.0%
20232023-12-31USD -1.4818.6%
20242024-12-31USD -0.49-67.1%
20252025-12-31USD -0.44-9.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.44

+0.2%

Gross Profit

$0.57

+0.1%

Gross Margin

39.18%

+0.6%

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.65

N/A

Employees

142

N/A

Net Income

-$31.00

+1.0%

EBITDA

-$31.07

+1.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$46.92

-6.3%

Total Debt

$19.33

+0.8%

Accounts Receivable

$0.87

+2.4%

Inventory

$0.00

N/A

Long Term Debt

$19.33

+0.8%

Short Term Debt

$0.00

N/A

Return on Assets

-168.79%

+2.2%

Return on Invested Capital

-331.40%

+3.0%

Free Cash Flow

-$19.30

+0.7%

Operating Cash Flow

-$19.28

+0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About SGMO

What is the current price of Sangamo Therapeutics?

Sangamo Therapeutics is trading at N/A per share.

What is the 52-week range for Sangamo Therapeutics?

Over the past 52 weeks, Sangamo Therapeutics has traded between N/A and N/A.

How much debt does Sangamo Therapeutics have?

As of the most recent reporting period, Sangamo Therapeutics reported total debt of $19.33M.

How much cash does Sangamo Therapeutics have on hand?

Sangamo Therapeutics reported $27.59M in cash and cash equivalents in its most recent financial results.

What is Sangamo Therapeutics’s dividend yield?

Sangamo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services